The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID-19 preventive measures: A threat to global public health.
作者信息
Islam Md Rabiul, Shahriar Mohammad, Bhuiyan Mohiuddin Ahmed
机构信息
Department of Pharmacy University of Asia Pacific Farmgate Dhaka Bangladesh.
出版信息
Health Sci Rep. 2022 Oct 13;5(6):e884. doi: 10.1002/hsr2.884. eCollection 2022 Nov.
Abstract
摘要
相似文献
1
The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID-19 preventive measures: A threat to global public health.最新的奥密克戎BA.4和BA.5谱系对新冠病毒预防措施构成挑战：对全球公共卫生的威胁。
Health Sci Rep. 2022 Oct 13;5(6):e884. doi: 10.1002/hsr2.884. eCollection 2022 Nov.
2
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.SARS-CoV-2 奥密克戎 BA.5：与关注的病毒变体相比，其对潜在体液反应的趋化性和逃逸能力以及对临床免疫疗法的耐药性不断进化。
EBioMedicine. 2022 Oct;84:104270. doi: 10.1016/j.ebiom.2022.104270. Epub 2022 Sep 18.
3
Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2.社论：世界卫生组织（WHO）变异关注谱系监测（VOC-LUM）以应对奥密克戎（或 B.1.1.529）SARS-CoV-2 谱系和亚谱系在全球范围内的传播
Med Sci Monit. 2022 Jul 1;28:e937676. doi: 10.12659/MSM.937676.
4
Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS-CoV-2 variants.与 SARS-CoV-2 三种主要变异株相关的临床结果和系统进化分析。
Eur J Clin Invest. 2023 Sep;53(9):e14004. doi: 10.1111/eci.14004. Epub 2023 May 2.
5
In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT-qPCR assays for SARS-CoV-2 detection using whole genome sequencing.基于全基因组测序的奥密克戎变异株 BA.4 和 BA.5 对 SARS-CoV-2 检测 RT-qPCR 检测方法敏感性影响的计算机评估。
J Med Virol. 2023 Jan;95(1):e28241. doi: 10.1002/jmv.28241. Epub 2022 Nov 8.
6
Omicron variant evolution on vaccines and monoclonal antibodies.奥密克戎变异株对疫苗和单克隆抗体的影响。
Inflammopharmacology. 2023 Aug;31(4):1779-1788. doi: 10.1007/s10787-023-01253-6. Epub 2023 May 19.
7
Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.初次感染 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 株后中和抗体的不同反应特征
Front Immunol. 2022 Jul 19;13:946318. doi: 10.3389/fimmu.2022.946318. eCollection 2022.
8
The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.奥密克戎变异株引发的 SARS-CoV-2 疫情、免疫逃逸和疫苗效力。
J Med Virol. 2023 Jan;95(1):e28138. doi: 10.1002/jmv.28138. Epub 2022 Sep 21.
9
Omicron new variant BA.2.86 (Pirola): Epidemiological, biological, and clinical characteristics - a global data-based analysis.奥密克戎新变体 BA.2.86（皮罗拉）：基于全球数据的流行病学、生物学和临床特征分析。
Eur Rev Med Pharmacol Sci. 2023 Oct;27(19):9470-9476. doi: 10.26355/eurrev_202310_33975.
10
Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.AZD7442（替沙格韦单抗-西加韦单抗）对新冠病毒奥密克戎亚变体中和作用的分子特征分析
Microbiol Spectr. 2023 Mar 6;11(2):e0033323. doi: 10.1128/spectrum.00333-23.
引用本文的文献
1
Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19.嵌合受体结合域疫苗设计与序贯免疫增强了针对新冠病毒的广泛中和抗体反应。
Front Immunol. 2025 Mar 27;16:1543212. doi: 10.3389/fimmu.2025.1543212. eCollection 2025.
2
Tracking SARS-CoV-2 and its variants in wastewater in Tunisia.追踪突尼斯废水中的 SARS-CoV-2 及其变体。
J Water Health. 2024 Aug;22(8):1347-1356. doi: 10.2166/wh.2024.377. Epub 2024 Aug 8.
3
Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies.广谱二价 mRNA 疫苗在临床前研究中对 SARS-CoV-2 变异株的有效性。
Emerg Microbes Infect. 2024 Dec;13(1):2321994. doi: 10.1080/22221751.2024.2321994. Epub 2024 Feb 29.
4
Development of multiplex allele-specific RT-qPCR assays for differentiation of SARS-CoV-2 Omicron subvariants.开发多重等位基因特异性 RT-qPCR 检测方法以区分 SARS-CoV-2 奥密克戎亚变体。
Appl Microbiol Biotechnol. 2024 Dec;108(1):35. doi: 10.1007/s00253-023-12941-2. Epub 2024 Jan 6.
5
Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprinting.接种疫苗后 BA.5-XBB.1.9.1 再感染的动态免疫景观揭示了对 XBB 感染 5 个月的保护期，并发生了免疫印迹的转变。
EBioMedicine. 2024 Jan;99:104903. doi: 10.1016/j.ebiom.2023.104903. Epub 2023 Dec 7.
6
Knowledge, attitude and practices towards SARS-CoV-2 genetic mutations and emerging variants among the population in Bangladesh: a cross-sectional study.孟加拉国人群对 SARS-CoV-2 基因突变和新兴变异体的知识、态度和实践：一项横断面研究。
BMJ Open. 2023 Nov 29;13(11):e073091. doi: 10.1136/bmjopen-2023-073091.
7
Impact of mutations defining SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 on Spike function and neutralization.定义新冠病毒奥密克戎亚变体BA.2.12.1和BA.4/5的突变对刺突蛋白功能和中和作用的影响
iScience. 2023 Oct 27;26(11):108299. doi: 10.1016/j.isci.2023.108299. eCollection 2023 Nov 17.
8
Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022).解析奥密克戎（BA.1、BA.2 和 BA.5）波动态及德尔塔克戎变异株出现：塞浦路斯 2021 年 10 月至 2022 年 10 月期间 SARS-CoV-2 流行的基因组流行病学。
Viruses. 2023 Sep 15;15(9):1933. doi: 10.3390/v15091933.
9
The WHO has declared the end of pandemic phase of COVID-19: Way to come back in the normal life.世界卫生组织已宣布新冠疫情大流行阶段结束：回归正常生活之路。
Health Sci Rep. 2023 Sep 5;6(9):e1544. doi: 10.1002/hsr2.1544. eCollection 2023 Sep.
10
Efficacy of novel SARS-CoV-2 rapid antigen tests in the era of omicron outbreak.奥密克戎变异株流行时期新型 SARS-CoV-2 快速抗原检测的效果。
PLoS One. 2023 Aug 10;18(8):e0289990. doi: 10.1371/journal.pone.0289990. eCollection 2023.
本文引用的文献
1
Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.南非西开普省奥密克戎变异株 BA.4 和 BA.5 驱动的疫情反弹期间与前几波相比实验室确诊的 SARS-CoV-2 感染的结果。
Int J Infect Dis. 2023 Feb;127:63-68. doi: 10.1016/j.ijid.2022.11.024. Epub 2022 Nov 24.
2
Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health.严重急性呼吸综合征冠状病毒2型奥密克戎（B.1.1.529）变异株的特征及其对全球公共卫生的新影响
Clin Pathol. 2022 Sep 20;15:2632010X221124908. doi: 10.1177/2632010X221124908. eCollection 2022 Jan-Dec.
3
A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery.一种强效的中和抗体通过鼻腔给药提供针对 SARS-CoV-2 奥密克戎和德尔塔变异株的保护。
Signal Transduct Target Ther. 2022 Aug 30;7(1):301. doi: 10.1038/s41392-022-01135-3.
4
Could the new BA.2.75 sub-variant lead to another COVID-19 wave in the world? - Correspondence.新的BA.2.75亚变体是否会在全球引发新一轮新冠疫情？——读者来信
Int J Surg. 2022 Sep;105:106861. doi: 10.1016/j.ijsu.2022.106861. Epub 2022 Aug 27.
5
Emerging novel sub-lineage BA.2.75: The next dominant omicron variant?新出现的BA.2.75亚谱系：下一个占主导地位的奥密克戎变体？
Int J Surg. 2022 Aug;104:106835. doi: 10.1016/j.ijsu.2022.106835. Epub 2022 Aug 11.
6
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.单克隆抗体治疗可快速促使 SARS-CoV-2 感染转为阴性。
Cell Rep Med. 2022 Jul 19;3(7):100678. doi: 10.1016/j.xcrm.2022.100678. Epub 2022 Jun 20.
7
Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2.社论：世界卫生组织（WHO）变异关注谱系监测（VOC-LUM）以应对奥密克戎（或 B.1.1.529）SARS-CoV-2 谱系和亚谱系在全球范围内的传播
Med Sci Monit. 2022 Jul 1;28:e937676. doi: 10.12659/MSM.937676.
8
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.奥密克戎 BA.4 和 BA.5 对疫苗和 BA.1 血清的抗体逃逸。
Cell. 2022 Jul 7;185(14):2422-2433.e13. doi: 10.1016/j.cell.2022.06.005. Epub 2022 Jun 9.
9
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.南非出现 SARS-CoV-2 奥密克戎变异株 BA.4 和 BA.5。
Nat Med. 2022 Sep;28(9):1785-1790. doi: 10.1038/s41591-022-01911-2. Epub 2022 Jun 27.
10
What Omicron's BA.4 and BA.5 variants mean for the pandemic.奥密克戎的BA.4和BA.5变体对疫情意味着什么。
Nature. 2022 Jun;606(7916):848-849. doi: 10.1038/d41586-022-01730-y.
Zotero 插件